Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

All Itching Is Not Benign; A Case of Refractory Hypereosinophilic Syndrome Treated with Off Label CD52 Inhibitor-Alemtuzumab

Rehan Ansari, MD, Elva Nora Osuna Salazar, MD, Nabeel Sarhill, MD, Laura E Garcia, MD, James Hanley, MD

Blood (2018) 132 (Supplement 1): 5485.

https://doi.org/10.1182/blood-2018-99-118271

Published: 2018

Journal Articles

SL-401, a Targeted Therapy Directed To The Interleukin-3 Receptor (IL-3R), Possesses Preclinical Cytotoxic Activity Against Chronic Eosinophilic Leukemia

Christopher Brooks, PhD, Vincent Macri, Arnaldo Albini, MD, Ivan Bergstein, MD, Eric Rowinsky, MD

Blood (2013) 122 (21): 4104.

https://doi.org/10.1182/blood.V122.21.4104.4104

Published: 2013

Journal Articles

Steroid-Sparing Effects of Anti-IL-5 Monoclonal Antibody (Mepolizumab) Therapy in Patients with HES: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.

Marc E. Rothenberg, MD, PhD, Gerald J. Gleich, MD, Florence E. Roufosse, MD, Lanny J. Rosenwasser, MD, Peter F. Weller, MD

Blood (2006) 108 (11): 373.

https://doi.org/10.1182/blood.V108.11.373.373

Published: 2006

Journal Articles

Safety and Tolerability of Anti-IL-5 Monoclonal Antibody (Mepolizumab) Therapy in Patients with HES: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.

Amy D. Klion, MD, Marc E. Rothenberg, MD, PhD, John J. Murray, MD,PhD, Anish Singh, MD, PhD, Hans-Uwe Simon, MD,PhD

Blood (2006) 108 (11): 2694.

https://doi.org/10.1182/blood.V108.11.2694.2694

Published: 2006

Journal Articles

Baseline Demographics and Disease Characteristics of Patients with Hypereosinophilic Syndrome in a Placebo-Controlled Trial Evaluating the Steroid-Sparing Effects of the Anti-IL-5 Monoclonal Antibody, Mepolizumab.

Gerald J. Gleich, MD, Lawrence B. Schwartz, MD PhD, William W. Busse, MD, Johannes Huss-Marp, MD, Scott R. Walsh, MD PhD

Blood (2006) 108 (11): 4899.

https://doi.org/10.1182/blood.V108.11.4899.4899

Published: 2006

NARROW

All Itching Is Not Benign; A Case of Refractory Hypereosinophilic Syndrome Treated with Off Label CD52 Inhibitor-Alemtuzumab

SL-401, a Targeted Therapy Directed To The Interleukin-3 Receptor (IL-3R), Possesses Preclinical Cytotoxic Activity Against Chronic Eosinophilic Leukemia

Steroid-Sparing Effects of Anti-IL-5 Monoclonal Antibody (Mepolizumab) Therapy in Patients with HES: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.

Safety and Tolerability of Anti-IL-5 Monoclonal Antibody (Mepolizumab) Therapy in Patients with HES: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.

Baseline Demographics and Disease Characteristics of Patients with Hypereosinophilic Syndrome in a Placebo-Controlled Trial Evaluating the Steroid-Sparing Effects of the Anti-IL-5 Monoclonal Antibody, Mepolizumab.

Email alerts

ASH Publications

American Society of Hematology

All Itching Is Not Benign; A Case of Refractory Hypereosinophilic Syndrome Treated with Off Label CD52 Inhibitor-Alemtuzumab

SL-401, a Targeted Therapy Directed To The Interleukin-3 Receptor (IL-3R), Possesses Preclinical Cytotoxic Activity Against Chronic Eosinophilic Leukemia

Steroid-Sparing Effects of Anti-IL-5 Monoclonal Antibody (Mepolizumab) Therapy in Patients with HES: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.

Safety and Tolerability of Anti-IL-5 Monoclonal Antibody (Mepolizumab) Therapy in Patients with HES: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.

Baseline Demographics and Disease Characteristics of Patients with Hypereosinophilic Syndrome in a Placebo-Controlled Trial Evaluating the Steroid-Sparing Effects of the Anti-IL-5 Monoclonal Antibody, Mepolizumab.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only